Source: https://profiles.bu.edu/Vaishali.Sanchorawala
Timestamp: 2019-04-24 05:47:10+00:00

Document:
Expertise includes: AL amyloidosis - clinical trials, treatment; Stem cell transplantation; Myeloma.
Trustees Of Columbia University In The City Of New York Cephalon, Inc.
Ehman EC, El-Sady MS, Kijewski MF, Khor YM, Jacob S, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Falk RH, Hyun H, Dorbala S. Early Detection of Multiorgan Light Chain (AL) Amyloidosis by Whole Body 18F-florbetapir PET/CT. J Nucl Med. 2019 Apr 06.View Related Profiles.
Sanchorawala V. Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Adv. 2019 Jan 22; 3(2):216-218. PMID: 30670538.
Phull P, Sanchorawala V, Brauneis D, Sloan JM, Siddiqi OK, Quillen K, Sarosiek S. High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. Bone Marrow Transplant. 2019 Jan 21.View Related Profiles.
Gupta VK, Brauneis D, Shelton AC, Quillen K, Sarosiek S, Sloan JM, Sanchorawala V. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Biol Blood Marrow Transplant. 2019 Jan 11.View Related Profiles.
Dennis M, Maoz A, Hughes D, Sanchorawala V, Sloan JM, Sarosiek S. Bortezomib ocular toxicities: Outcomes with ketotifen. Am J Hematol. 2019 Mar; 94(3):E80-E82.View Related Profiles.
Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, Havasi A. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019 Feb; 95(2):405-411.View Related Profiles.
McCausland KL, Quock TP, Rizio AA, Bayliss MS, White MK, Guthrie SD, Sanchorawala V. Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis. Br J Haematol. 2018 Nov 22. PMID: 30467849.
Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25; 4(1):38. PMID: 30361521.
Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019 Jan 17; 133(3):215-223.View Related Profiles.
Nguyen VP, Rosenberg A, Mendelson LM, Comenzo RL, Varga C, Sanchorawala V. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. Amyloid. 2018 Sep; 25(3):156-159.View Related Profiles.
Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2018 Sep; 24(9):1823-1827.View Related Profiles.
Sarosiek S, Quillen K, Sloan JM, Brauneis D, Sanchorawala V. Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. Blood. 2018 Aug 16; 132(7):755-757.View Related Profiles.
White PS, Phull P, Brauneis D, Sloan JM, Quillen K, Sarosiek S, Sanchorawala V. High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers. Bone Marrow Transplant. 2018 Dec; 53(12):1593-1595.View Related Profiles.
Siddiqi OK, Sanchorawala V, Ruberg FL. Echocardiography and Survival in Light Chain Cardiac Amyloidosis: Back to Basics. Circ Cardiovasc Imaging. 2018 May; 11(5):e007826.View Related Profiles.
Pudusseri A, Smith I, Sarnacki D, Brauneis D, Shelton A, Sanchorawala V, Sloan JM, Sarosiek S, Quillen K. Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients. Transfus Apher Sci. 2018 Jun; 57(3):411-415.View Related Profiles.
Ding Y, Francis J, Gautam A, Pelletier L, Sanchorawala V, Quillen K. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection?. Clin Nephrol. 2018 Apr; 89(4):252-259.View Related Profiles.
Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. Amyloid. 2018 Jun; 25(2):139-140.View Related Profiles.
Havasi A, Doros G, Sanchorawala V. Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2018 May; 93(5):E129-E132.View Related Profiles.
Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid. 2018 Mar; 25(1):1-7.View Related Profiles.
Nguyen VP, Brauneis D, Kaku M, Sloan JM, Sarosiek S, Quillen K, Shelton AC, Sanchorawala V. Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2018 03; 53(3):371-373.View Related Profiles.
White MK, McCausland KL, Sanchorawala V, Guthrie SD, Bayliss MS. Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Relat Outcome Meas. 2017; 8:157-167. PMID: 29263707.
Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biol Blood Marrow Transplant. 2018 01; 24(1):127-132.View Related Profiles.
Sanchorawala V, McCausland KL, White MK, Bayliss MS, Guthrie SD, Lo S, Skinner M. A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. Br J Haematol. 2017 Nov; 179(3):461-470.View Related Profiles.
Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL, Sanchorawala V, Varga C. The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplant. 2017 09; 52(9):1349-1351.View Related Profiles.
Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood. 2017 09 14; 130(11):1383-1386.View Related Profiles.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 Aug 03; 130(5):597-605. PMID: 28550039.
Graham MS, Pudusseri A, Helgager J, Narendra DP, De Girolami U, Pinkus GS, Sanchorawala V, Miyawaki E. A Woman in Her 40s With Headache and New-Onset Seizures. JAMA Neurol. 2017 Apr 01; 74(4):476-480. PMID: 28241235; DOI: 10.1001/jamaneurol.2016.2961;.
Pulido V, Doros G, Berk JL, Sanchorawala V. The six-minute walk test in patients with AL amyloidosis: a single centre case series. Br J Haematol. 2017 May; 177(3):388-394.View Related Profiles.
Uwumugambi NA, Sanchorawala V, Shelton AC, Stern L, Gordon CE. Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis. Am J Kidney Dis. 2017 Feb; 69(2):317-319.View Related Profiles.
Shu J, Lo S, Phillips M, Sun F, Seldin DC, Berenbaum I, Berk JL, Sanchorawala V. Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid. 2016 Sep; 23(3):188-193.View Related Profiles.
Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016 Oct; 30(10):1979-1986. PMID: 27416985; DOI: 10.1038/leu.2016.191;.
Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016 10; 91(10):E458-60.View Related Profiles.
Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016 Aug 25; 128(8):1059-62.View Related Profiles.
Dittus C, Uwumugambi N, Sun F, Sloan JM, Sanchorawala V. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Sep; 22(9):1729-1732.View Related Profiles.
Arun M, Sloan SB, Shelton A, Sanchorawala V. Penile ulcers complicating systemic AL amyloidosis: a case report. Amyloid. 2016 Sep; 23(3):203-204. PMID: 27187183.
Lee SY, Meehan RS, Seldin DC, Sloan JM, Quillen K, Shelton A, Brauneis D, Sanchorawala V. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplant. 2016 Oct; 51(10):1318-1322.View Related Profiles.
Sanchorawala V, Gale RP. David C Seldin, MD, PhD: scientist, clinician, teacher, gentleman, 1957-2015. Bone Marrow Transplant. 2016 Mar; 51(3):323. PMID: 26931484; DOI: 10.1038/bmt.2015.340;.
Sissoko M, Sanchorawala V, Seldin D, Sworder B, Angelino K, Broce M, Berk J, Sloan JM. Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid. 2015; 22(4):229-35.View Related Profiles.
Bever KM, Masha LI, Sun F, Stern L, Havasi A, Berk JL, Sanchorawala V, Seldin DC, Sloan JM. Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica. 2016 Jan; 101(1):86-90.View Related Profiles.
PMID: 26452981; PMCID: PMC4697895; DOI: 10.3324/haematol.2015.133900;.
Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015 Nov 12; 126(20):2345-7.View Related Profiles.
Bosch N, Renteria AS, Quillen K, Brauneis D, Santilli J, Kim D, Sanchorawala V. Nonoperative Management of Spontaneous Splenic Rupture in a Patient with Light-Chain Amyloidosis: A Case Report. J Vasc Interv Radiol. 2015 Oct; 26(10):1578-80.View Related Profiles.
Lee SY, Brauneis D, Stern L, Sanchorawala V. Optimal dosing of high-dose melphalan prior to autologous hematopoietic stem cell transplantation in a patient with AL amyloidosis and a solitary kidney. Hematol Oncol Stem Cell Ther. 2016 Jun; 9(2):86-8.View Related Profiles.
Skinner M, Sanchorawala V. In memoriam David C. Seldin, MD, PhD. Amyloid. 2015; 22(3):145-6.View Related Profiles.
Skinner M, Sanchorawala V. In memoriam David C. Seldin, MD, PhD. Amyloid. 2015 Aug 07; 1-2.View Related Profiles.
Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1445-51.View Related Profiles.
Renteria AS, Sanchorawala V, Niehaus ED, Sun F, Semigran MJ, Seldin DC. Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis. Bone Marrow Transplant. 2015 Jun; 50(6):868-9.View Related Profiles.
Sanchorawala V. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Hematol Oncol Clin North Am. 2014 Dec; 28(6):1131-44. PMID: 25459183; DOI: 10.1016/j.hoc.2014.08.013;.
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014 Oct 16; 124(16):2498-506. PMID: 25202139; PMCID: PMC4199951; DOI: 10.1182/blood-2014-04-568329;.
Freeman B, Brauneis D, Seldin DC, Quillen K, Sloan JM, Renteria AS, Shelton AC, Teschner T, Finn KT, Sanchorawala V. Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis. Bone Marrow Transplant. 2014 Oct; 49(10):1345-6.View Related Profiles.
Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid. 2014 Sep; 21(3):149-53.View Related Profiles.
Lichtman EI, Seldin DC, Shelton A, Sanchorawala V. Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. Am J Hematol. 2014 Jul; 89(7):706-8.View Related Profiles.
Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014 Feb; 99(2):209-21. PMID: 24497558; PMCID: PMC3912950; DOI: 10.3324/haematol.2013.087619;.
Zonder J, Houde C, Tuchman S, Kukreti V, Sanchorawala V, Pregja S, Reichel KA, Burt SM, Neveux C, Matous J. Blood. A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease. 2014.
Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant. 2013 Nov; 48(12):1537-42.View Related Profiles.
PMID: 23852321; PMCID: PMC3855173; DOI: 10.1038/bmt.2013.98;.
Girnius S, Seldin DC, Cibeira MT, Sanchorawala V. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. J Clin Oncol. 2013 Jul 20; 31(21):2749-50.View Related Profiles.
Sanchorawala V, Shelton AC, Zeldis JB, Seldin DC. Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide. Am J Hematol. 2013 Aug; 88(8):719.View Related Profiles.
Sarosiek S, Seldin DC, Berk JL, Sanchorawala V. A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature. Amyloid. 2013 Jun; 20(2):127-30.View Related Profiles.
Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. Transpl Infect Dis. 2013 Apr; 15(2):187-94.View Related Profiles.
Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013 May; 98(5):789-92.View Related Profiles.
PMID: 23144200; PMCID: PMC3640126; DOI: 10.3324/haematol.2012.075192;.
Freeman B, Sloan JM, Seldin DC, Cowan AJ, Ruberg FL, Sanchorawala V. Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. Amyloid. 2012 Sep; 19(3):156-60.View Related Profiles.
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012 Nov; 26(11):2317-25.View Related Profiles.
Seldin DC, Sanchorawala V. Amyloidomics comes of age. Blood. 2012 Feb 23; 119(8):1795-6.View Related Profiles.
Sanchorawala V, Seldin DC. AL amyloidosis: who, what, when, why, and where. Oncology (Williston Park). 2012 Feb; 26(2):164, 166, 169.View Related Profiles.
Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res. 2012; 2(1):9-17. PMID: 22432083; PMCID: PMC3301435.
Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 2011 Dec; 96(12):1890-2.View Related Profiles.
PMID: 21859734; PMCID: PMC3232278; DOI: 10.3324/haematol.2011.049858;.
Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM. 2011 Nov; 104(11):957-70. PMID: 21752867; DOI: 10.1093/qjmed/hcr105;.
Seldin DC, Berk JL, Sam F, Sanchorawala V. Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment. Heart Fail Clin. 2011 Jul; 7(3):385-93.View Related Profiles.
PMID: 21749890; PMCID: PMC3135875; DOI: 10.1016/j.hfc.2011.03.009;.
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28; 118(4):865-73. PMID: 21562045; DOI: 10.1182/blood-2011-02-334227;.
Seldin DC, Berk JL, Sam F, Sanchorawala V. Amyloidotic cardiomyopathy: Multidisciplinary approach to diagnosis and treatment. In: Heart Failure Clinics, Ed by Daniel J. Lenihan and Douglas B. Sawyer. 2011.
Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A, Zeldis JB, Sanchorawala V. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010 Dec 2; 116(23):5071-2.View Related Profiles.
Sanchorawala V, Seldin DC, Berk JL, Sloan JM, Doros G, Skinner M. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):469-72.View Related Profiles.
Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010 Oct 27; 90(8):905-11.View Related Profiles.
PMID: 20733534; PMCID: PMC2964067; DOI: 10.1097/TP.0b013e3181f10edb;.
Quillen K, Seldin DC, Finn KT, Sanchorawala V. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplant. 2011 Jul; 46(7):976-80.View Related Profiles.
Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB, Seldin DC. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood. 2010 Sep 16; 116(11):1990-1.View Related Profiles.
Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, Zeldis JB, Dember LM. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant. 2011 Mar; 26(3):881-6.View Related Profiles.
PMID: 20693160; PMCID: PMC3108346; DOI: 10.1093/ndt/gfq482;.
Girnius S, Seldin DC, Quillen K, Dember LM, Segal A, Sanchorawala V. Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation. Bone Marrow Transplant. 2011 Jan; 46(1):161-2.View Related Profiles.
Sanchorawala V, Jacobson DR, Seldin DC, Buxbaum JN. The Amyloidoses. In Williams Textbook of Hematology, Ed by Thomas Kipps and Marshall Lichtmann. 2010.
Sanchorawala V, Bolejack V, Crowley J, Hoering A, Finn KT, Fennessey S, Seldin DC, Barlogie B. Amyloid. Modified high dose melphalan and autologous stem cell transplantation (HDM/SCT) in the treatment of AL amyloidosis: analysis of a Southwest Oncology Group trial. 2010.
Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Ann Hematol. 2010 Jun; 89(6):579-84.View Related Profiles.
Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20; 114(8):1489-97. PMID: 19498019; DOI: 10.1182/blood-2009-02-203398;.
Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009 Jul; 94(7):1029-32.View Related Profiles.
PMID: 19454500; PMCID: PMC2704317; DOI: 10.3324/haematol.2008.001925;.
Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction. Bone Marrow Transplant. 2010 Jan; 45(1):21-4.View Related Profiles.
PMID: 19421171; PMCID: PMC3672063; DOI: 10.1038/bmt.2009.94;.
Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma. 2008 Jun; 49(6):1108-15. PMID: 18452093; DOI: 10.1080/10428190802023707;.
Sanchorawala V. AL (Immunoglobulin Light-Chain) Amyloidosis. In Myeloma Therapy: Pursuing the Plasma Cell, Ed by Sagar Lonial. Springer. New York. 2008.
Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid. 2007 Dec; 14(4):261-9.View Related Profiles.
Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007 Nov 15; 110(10):3561-3.View Related Profiles.
Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant. 2007 Sep; 40(6):557-62.View Related Profiles.
Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease--diagnosis and treatment. Clin J Am Soc Nephrol. 2007 Jul; 2(4):858-67.View Related Profiles.
Seldin DC, Rosenzweig M, Finn KT, Fennessey S, Shelton A, Zeldis JB, Skinner M, Sanchorawala V. Blood. Durable responses to lenalidomide (Revlimid (R)) in patients with AL amyloidosis: Follow up of a phase II trial. 2007.
Seldin DC, Sanchorawala V. Adapting to AL amyloidosis. Haematologica. 2006 Dec; 91(12):1591-5.View Related Profiles.
Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006 Nov; 1(6):1331-41. PMID: 17699366.
Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007 Jan 15; 109(2):492-6.View Related Profiles.
Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood. 2006 Dec 1; 108(12):3945-7.View Related Profiles.
Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, Skinner M, Seldin DC, Sanchorawala V. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):339-43.View Related Profiles.
Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Skinner M, Seldin DC. A phase II trial of lenalidomide for patients with AL amyloidosis. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7524.View Related Profiles.
Finn K, Fennessey S, Seldin D, Sanchorawala V, Shelton A, Allten S, Antonelli C. Skin reactions associated with oral Revlimid (lenalidomide) in al amyloidosis (ALA); Patient teaching encouraging prompt reporting, and clinical assessment. Oncology nursing forum. 2006; 33(2):395.
Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005 Oct; 36(7):597-600.View Related Profiles.
Berk JL, Wiesman JF, Skinner M, Sanchorawala V. Diaphragm paralysis in primary systemic amyloidosis. Amyloid. 2005 Sep; 12(3):193-6.View Related Profiles.
Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2005 Mar; 35(6):567-75.View Related Profiles.
Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, Berk JL, Dember LM, Falk RH, Skinner M. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004 Sep 15; 104(6):1888-93.View Related Profiles.
Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004 Feb; 33(4):381-8.View Related Profiles.
Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol. 2003 Oct; 74(2):131-5.View Related Profiles.
Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest. 2003 Sep; 124(3):969-77.View Related Profiles.
Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int. 2003 May; 63(5):1868-73.View Related Profiles.
Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int. 2003 Mar; 63(3):1051-7.View Related Profiles.
Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM, Finn KT, Skinner M. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol. 2002 Jun; 117(4):886-9.View Related Profiles.
Akpek G, Lenz G, Lee SM, Sanchorawala V, Wright DG, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo RL. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant. 2001 Dec; 28(12):1105-9.View Related Profiles.
Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001 Oct; 28(7):637-42.View Related Profiles.
Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001 Mar 15; 97(6):1885-7.View Related Profiles.
Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, Berk JL, Dember LM, Falk R, Finn K, Skinner M, Vosburgh E. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol. 1999 Mar; 104(3):553-9.View Related Profiles.
Fan-Harvard P, Sanchorawala V, Oh J, Moser EM, Smith SP. Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures. Ann Pharmacother. 1994 Jul-Aug; 28(7-8):869-72. PMID: 7949502.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.